公开(公告)号：US11786534B2

公开(公告)日：2023-10-17

申请号：US17430208

申请日：2020-02-14

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Fuyuki Yamamoto ,  Takashi Mizutani ,  Hidefumi Kasuga ,  Hirokazu Fuchida ,  Shoki Hara ,  Yu Kobayakawa ,  Yoshio Ogino

IPC分类号： A61K31/519 ,  C07D487/04 ,  A61K31/5377 ,  A61P35/00 ,  C07D519/00

CPC分类号： A61K31/5377 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

摘要： The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10889555B2

公开(公告)日：2021-01-12

申请号：US16751555

申请日：2020-01-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  C07D413/12 ,  A61P35/00 ,  C07D417/12 ,  C07D491/107 ,  C07D413/14

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

公开(公告)号：US11634395B2

公开(公告)日：2023-04-25

申请号：US17000807

申请日：2020-08-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  A61P35/00 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/107

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.

公开(公告)号：US20200157066A1

公开(公告)日：2020-05-21

申请号：US16751555

申请日：2020-01-24

申请人： Taiho Pharmaceutical Co., Ltd.

发明人： Seiji Miyahara ,  Hiroyuki Ueno ,  Shoki Hara ,  Yoshio Ogino

IPC分类号： C07D271/07 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D491/107 ,  A61P35/00

摘要： The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.